Biodistribution and radiation dosimetry of the hypoxia marker F-18-HX4 in monkeys and humans determined by using whole-body PET/CT

Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA.
Nuclear Medicine Communications (Impact Factor: 1.37). 12/2010; 31(12):1016-24. DOI: 10.1097/MNM.0b013e3283407950
Source: PubMed

ABSTRACT F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose of F-HX4 using whole-body PET/computed tomography (CT) scans in monkeys and humans.
Successive whole-body PET/CT scans were done after the injection of F-HX4 in four healthy humans (422±142 MBq) and in three rhesus monkeys (189±3 MBq). Biodistribution was determined from PET images and organ doses were estimated using OLINDA/EXM software.
The bladder, liver, and kidneys showed the highest percentage of the injected radioactivity for humans and monkeys. For humans, approximately 45% of the activity is eliminated by bladder voiding in 3.6 h, and for monkeys 60% is in the bladder content after 3 h. The critical organ is the urinary bladder wall with the highest absorbed radiation dose of 415±18 (monkeys) and 299±38 μGy/MBq (humans), in the 4.8-h bladder voiding interval model. The average value of effective dose for the adult male was estimated at 42±4.2 μSv/MBq from monkey data and 27±2 μSv/MBq from human data.
Bladder, kidneys, and liver have the highest uptake of injected F-HX4 activity for both monkeys and humans. The urinary bladder wall receives the highest dose of F-HX4 and is the critical organ. Thus, patients should be encouraged to maintain adequate hydration and void frequently. The effective dose of F-HX4 is comparable with that of other F-based imaging agents.

Download full-text


Available from: Mohan Doss, Mar 27, 2014
1 Follower
  • Source
    • "The field of view for CT and PET imaging was positioned on the primary tumor. [ 18 F]HX4 was produced as described in previous publications [18] [19] [20] [21]. The injected activity of [ 18 F]HX4 was 423 ± 72 MBq based on a previous phase I trial [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: [(18)F]HX4 is a promising hypoxia PET-tracer. Uptake, spatio-temporal stability and optimal acquisition parameters for [(18)F]HX4 PET imaging were evaluated in non-small cell lung cancer (NSCLC) patients. [(18)F]HX4 PET/CT images of 15 NSCLC patients were acquired 2h and 4h after injection (p.i.). Maximum standardized-uptake-value (SUVmax), tumor-to-blood-ratio (TBRmax), hypoxic fraction (HF) and contrast-to-noise-ratio (CNR) were determined for all lesions. To evaluate spatio-temporal stability, DICE-similarity and Pearson correlation coefficients were calculated. Optimal acquisition-duration was assessed by comparing 30, 20, 10 and 5min acquisitions. Considerable uptake (TBR >1.4) was observed in 18/25 target lesions. TBRmax increased significantly from 2h (1.6±0.3) to 4h p.i. (2.0±0.6). Uptake patterns at 2h and 4h p.i. showed a strong correlation (R=0.77±0.10) with a DICE similarity coefficient of 0.69±0.08 for the 30% highest uptake volume. Reducing acquisition-time resulted in significant changes in SUVmax and CNR. TBRmax and HF were only affected for scan-times of 5min. The majority of NSCLC lesions showed considerable [(18)F]HX4 uptake. The heterogeneous uptake pattern was stable between 2h and 4h p.i. [(18)F]HX4 PET imaging at 4h p.i. is superior to 2h p.i. to reach highest contrast. Acquisition time may be reduced to 10min without significant effects on TBRmax and HF.
    Radiotherapy and Oncology 09/2013; 109(1). DOI:10.1016/j.radonc.2013.08.031 · 4.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with non-invasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18F-fluorodeoxyglucose (18F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors. KeywordsMolecular imaging–Oncologic tracer–PET
    03/2011; 45(1):1-14. DOI:10.1007/s13139-011-0075-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: This manuscript will concern the positron emission tomography (PET) tracers, their main biological targets and the main clinical research studies with these tracers. A comparison of the tracers available in France will be done.
    Medecine Nucleaire 08/2011; 35(8):433-444. DOI:10.1016/j.mednuc.2011.05.011 · 0.16 Impact Factor
Show more